[
    " DAMGO, ECso =0.77(6.11 \u00b10.16) mM. Bias factor toward G-protein for IBNtxA is 404 against D AMGO as a control at mMOR. FIG. 2C MP1202 targets the TM5- ECL2 region and is a G-protein biased agonist at mMOR: The preferred docking pose of MP1202 (chair form, stick) at an active state of MOR. The saturated ringC in MP1202 leads to interaction of the ligand in the ECL2 and TM5 region. MP1202 (triangle) is a G-biased partial agonist in mMOR in BRET assays measuring G-protein activation and arrestin recruitment compared to DAMGO (circle). Gi: MP1202, ECso = 0.63 (9.2\u00b10.09) nM, Emax = 61\u00b11.5 and DAMGO ECso = 6.31 (8.2\u00b10.07) nM. Arrestin: MP1202, ECso = 3140 (5.5\u00b10.28) nM, E<sub>max</sub> <sup>:::</sup> 53 \u00b1 1.6 and DAMGO ECso = 14 (6.9\u00b10.15) nM. Bias factor toward G protein: 58 for MP1202, respectively (n = 3) against DAMGO as a control at mMOR. FIG. 2D MP1207 and MP1208 target the TM5-ECL2 region and show<sup>7</sup> no arrestin recruitment at mMOR: \n\n Docking results showed that /\u00ab-amino methyl (MP1207) or /\u00ab-guanidinoraethy! (MP1208) moieties (replacing an iodo group in MP1202) forced these compounds in chair form preferred confirmation at MOR (chair form in dark stick and boat form in light stick). MP1207 (diamond) and MP1208 (triangle) are partial agonists at mMOR in BRET assays compared to DAMGO (circle). At MOR, chair forms of MP1207and MP1208 introduce additional interactions between \u00ab/-amino or \u00ab/-guanidine group and D218<sup>tCL2</sup> and T220<sup>iiCL2</sup>. Gi: MP1207, EC50 = 3.61 (8.44 \u00b1 0.26) nM, E<sub>max</sub> = 42 : 2.6: MP1208, ECso 2.27 (8.64 \u00b1 0.29) nM, E<sub>Wx</sub> = 41 . 3 and DAMGO, EC50 = 3.27(8.49\u00b10.08) nM. Arrestin: no arrestin recruitment was observed for both agonists thereby limiting to calculate their bias factors against DAMGO as a control at mMOR. FIG. 2E MP1305 and MP1601 target the TM5-ECL2 region and show no arrestin recruitment at mMOR: Chair and boat forms of MP1305 and MP1601 at an active state MOR (in light) are shown. Docking modes of MPI305 and MP1601 are analogous and they both maintain chair confirmation at MOR and are biased towards G-protein. In BRET assays using mMOR, MP1305 (square) and MP1601 (triangle) are partial agonists compared to DAMGO (circle) with no measurable arrestin recruitment, Gi: MP1305, EC 50 = 0.74(9.1 \u00b1 0.12)nM, E<sub>max</sub> = 72\u00b12 and DAMGO, ECso - 3.3(8.4\u00b10.08) nM and MP1601, ECso = 2.2(8.6 \u00b1 0.3)nM, E<sub>n</sub> = 49\u00b13 and DAMGO, ECso = 0.9(9.0\u00b10.1 ) nM. Arrestin : no arrestin recruitment was observed for both agonists against DAMGO as a control at mMOR. Data from BRET assays using rodent opioid receptors were normalized to E<sub>max</sub> of the corresponding controls, DAMGO where, the dose response curves were fit using a three-parameter logistic equation in GraphPad Pris and the data are presented as mean ECsofpECso \u00b1 SEM) for assays run in triplicate. In summary', targeting TM5-ECL2 and ring C taking chair form leads to bias at MOR in both rodents as well as human receptors with analogs. </p> [0026] FIGS. 3A-3E show's the characterization of ligands (MP1104, IBNtxA, MP1202, MP1207, MP1208, MP1305 and MP1601) at rat kappa opioid receptor (rKOR) using BRET assays-chemical structures, docking in MOR, G-protein activity and arrestin recruitment, docking scores of chair/boat and bias factors. FIG. 3A MP1104 targets the TM2- TM3 region and is a balanced agonist at mKOR: The preferred docking pose of MP1104 (boat form, stick) at an active state of KOR is shown. The iodophenylamido moiety aligns in the hydrophobic pocket between TM2 and TM3 in KOR, a cavity lined with VI I8<sup>2</sup>\u00b7<sup>63</sup>, W124<sup>ECl1</sup> and L135<sup>J</sup>-<sup>2y</sup>. In addition, polar residue Q115<sup>2 o0</sup> adopts a slightly different conformation which allow",
    " ligand with ring-C chair form leads to preferred G-protein signaling, whereas TM2-TM3 engagement and ring-C boat form leads to balanced G-protein and arrestin signaling. FIG. 4B Structures of the studied /w&amp;p-substituted aryiamidoepoxymorphinans (MP1104, MP1202, IBNtxA, MP1305, MP1207, MP1208, MP1209, MP1210), /w-iodoaiylamidomorphinan, (MP1601), and 6'GNTL </p> [0028] FIGS. 5A-5I show's IBNtxA showed a balanced agonism at KOR and G-protein biased agonism at MOR. FIGS, 5A &amp; SB At hMOR, IBNtxA (square) is a G-protein biased agonist compared with DAMGO (circle) Gi: ECso - 0.07(10.2 \u00b1 0.006) nM, Emax = 95+2; DAMGQ (circle), ECso = 0.99(9.0\u00b10.Q07)nM and Arrestin: IBNtxA, ECso = 5.86(8.2\u00b10.002) nM, E<sub>max</sub> = 29+0.02; DAMGO, ECso =14.16(7.9+0.003) nM. Bias factor toward G-protein for IBNtxA is 23 against DAMGO as a control at hMOR. FIGS. 5C &amp; 5D At hKOR, IBNtxA (circle) is a balanced agonist in cAMP inhibition and Tango-arrestin recruitment assays compared to U50,488H (square). Gi: IBNtxA, ECso = 0.47 (12.3 \u00b1 0.06)pM, E<sub>max</sub> = 106+0.7; U50,488H, ECso = 0.076(10 l\u00b10.04)nM and Arrestin: IBNtxA, ECso = 0.0 ! 3( i 0.9. 0.07) nM, \n\n E<sub>max</sub>\u2014 109\u00b11.8; U50,488, ECso =3.63(8.4\u00b10.03) nM. Bias factor toward G- protein is 0.2 for IBNtxA against U50,488H as a control at hKOR. FIGS. 5F &amp; 5G However, at mMOR, it is a G-biased partial agonist compared to DAMGO (circle) in BRET assays with Gi: ECso - 0.054(10.3 \u00b1 0.02) nM, E<sub>max</sub> = 59\u00b12.2; DAMGO, EC50 = 12.9(7.8 : 0.06) nM and Arrestin: IBNtxA, ECso <sup>:::</sup> 1 1 .32(4.9 : 0 3 ) mM, E<sub>max</sub> = <sup>\"</sup>5 \u00b7 15.9; DAMGO, ECso =0.77(6.1 1\u00b10.16) mM. Bias factor toward G-protein for IBNtxA is 404 against DAMGO as a control at mMOR. FIGS. 511 &amp; 51 In BRET assays using rKOR, IBNtxA is a balanced agonist compared with U50,488H (square), Gi: IBNtxA, ECso = 0.064(10.2 \u00b1 0.1) nM, E<sub>max</sub> - 101\u00b12.3; U50,488, ECso = 27.7(7.6\u00b10.01)nM and Arrestin: IBNtxA, ECso = 1.23(8.9\u00b10.02) nM, E<sub>m</sub>a<sub>x</sub> = 133\u00b17.3; U50,488H, ECso =345.6(6.4\u00b10.03) nM. Bias factor toward G-protein is 0.6 for IBNtxA against U50,488H as a control at rKOR. FIGS. 5E &amp; 5J The docking poses of IBNtxA (chair form, dark stick) and (boat form, light stick) at an active state of MOR and KOR are shown. At MGR, the saturated ring C in IBNtxA leads to interaction of the ligand in the ECL2 and TM5 region leading to a preference of chair form shown by an arrow. At KOR, the iodophenylamido moiety of IBNtxA aligns in the hydrophobic pocket between TM2 and TM3 in KOR, a cavity lined with VI 18<sup>2</sup>\u00b7<sup>63</sup>, W124<sup>ECL1</sup> and L135<sup>3</sup>\u00b7<sup>29</sup> similar to MP1202. This flip of ring C conformation from chair to boat going is shown by a blue arrow. Data from both cAMP inhibition and Tango arrestin assays using human opioid receptors and BRET assays using rodent opioid receptors were normalized to E<sub>max</sub> of the corresponding controls, U50,488H and DAMGO. The dose response curves were fit using a three-parameter logistic equation in GraphPad Pris and the data are presented as mean ECsoCpECso \u00b1 SEM) for assays run in triplicate. Preference for chair form correlates with G-protein bias while preference for boat form correlates with arrestin recruitment. </p> [0029] FIG. 6 show the preferred docking pose of known KOR biased ligand 6\u2019GNTI (chair form, orange stick) at an active state of KOR with the guanidino group engaging a region between TM5 and EC12. Note: possible engagement of residues D223 and E209 similar to MP1207 and MP1208 in TM5-ECL2 region. </p> [0030] FIGS. 7A-7H show meta- Amino (MP1207) and meta-guanidi o (MP1208) analogs prefer the chair conformation and target the TM5-ECL2 region and are G-protein biased agonists at KOR and MOR: FIGS. 7A &amp; 7B Unlike MP1202, MP1207 (diamond) and MP1208 (triangle) are full G protein biased agonists at hKOR in cAMP inhibition and Tango- arrestin recruitment assays compared to U50, 488 (circle). Gi : MP1207, EC 50 <sup>::::</sup> 0.1 1 (9.98 \u00b1 0.07) nM, Emax = 90\u00b11.7; MP1208, EC50 = 0.14 (9.9 \u00b1 0.07) nM, Emax = 96\u00b11.9; and U50,488, EC50 - 0.64(9.2 : 0 06) nM. Arrestin: MP1207, ECso - 3 97(8 4 - 0. 1 8) nM, E<sub>ma</sub> = 37\u00b12, \n\n MP1208, ECso = 16.41 (7 79\u00b10.14) nM, Emax = 48\u00b12 4, and 1150,488, ECso =7.55(8.12\u00b10.06) nM. Bias factor toward G protein: 8 and 23 for MP1207 and MP1208 respectively against U50,488 as a control at hKOR. FIGS. 7C &amp; 71) Docking results showed that amino methyl (MP1207) or guanidino (MP1208) moieties (replacing an iodo group in MP1202) forced these compounds in chair form preferred confirmation at KOP. (chair form in dark stick and boat form in light stick). Unlike boat MP1202, chair MP1207 at AKOR may form a new salt bridge interaction between amino group and 1)223<sup>\" \u00be :</sup> and E209<sup>ECi 2</sup> pulling amidophenyl moiety away from the hydrophobic pocket between TM2 and TM3 (FIG. 7C). Likewise, chair MP1208 forms salt bridge interactions between guanidino group and D223 <sup>35</sup> as well as with E209<sup>ECL2</sup> FIG. 7D The flip in conformation of ringC from boat to chair for both MP1207 and MP1208 is shown by an arrow. FIGS. 7E &amp; 7F MP1207 (diamond) and MP1208 (triangle) are partial agonists at hMOR in cAMP inhibition and Tango-arrestin recruitment assays compared to DAMGO (circle). Gi: MP1207, ECso = 0.034 (10.47 \u00b1 0.15) nM, E<sub>imK</sub> = 33\u00b11.4; MP1208, ECso = 0.008 (8.73 \u00b1 0.12) nM, Ema = 42\u00b11.3; and DAMGO, ECso = 1.86(8.73\u00b10.06) nM. Arrestin: Essentially, no arrestin recruitment was observed for both agonists MP1207 and MP1208 thereby limiting",
    "ormulation, or drug delivery' system. Excipients may be used, for example, to stabilize the composition, to bulk up the composition (thus often referred to as\u201cbulking agents,\u201d\u201cfillers,\u201d or\u201cdiluents\u201d when used for this purpose), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Excipients include pharmaceutically acceptable versions of antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles. The main excipient that serves as a medium for conveying the active ingredient is usually called the vehicle. Excipients may also be used in the manufacturing process, for example, to aid in the handling of the active substance, such as by facilitating powder flowabiiity or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation or aggregation over the expected shelf life. The suitability of an excipient will ty pically vary depending on the route of administration, the dosage form, the active ingredient, as well as other factors. </p>[00102] The term\u201chydrate\u201d when used as a modifier to a compound means that the compound has less than one (e.g, hemihydrate), one (e.g., monohydrate), or more than one (e.g, dihydrate) water molecules associated with each compound molecule, such as in solid forms of the compound. </p>[00103] As used herein, the term\u201cIC50\u201d refers to an inhibitor}<sup>,</sup> dose which is 50% of the maximum response obtained. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological, biochemical or chemical process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. </p>[00104] An\u201cisomer\u201d of a first compound is a separate compound in which each molecule contains the same constituent atoms as the first compound, but where the configuration of those atoms in three dimensions differs. </p>[00105] As used herein, the term\u201cpatient\u201d or\u201csubject\u201d refers to a living mammalian organism, such as a human, monkey, cow, horse, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof. In certain embodiments, the patient or subject is a primate. Non- limiting examples of human patients are adults, juveniles, infants and fetuses. \n\n [00106] As generally used herein \u201cpharmaceutically acceptable\u201d refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio. </p>[00107] \u201cPharmaceutically acceptable salts\u201d means salts of compounds di sclosed herein which are pharmaceutically acceptab",
    "gf000073_0001\" path=\"imgf000073_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/802032640/WO/20210114/A1/002021/00/73/66/imgf000073_0001.tif\"/>\n 1.39 \u00b1 0.87<sup>b</sup> <sup>a</sup> Competition studies were performed with the indicated compounds against <sup>125</sup>IBNtxA (0.1 nM) in membranes from CHO cells stably expressing the indicated cloned mouse opioid receptors. K, values were calculated from the IC<sub>\u00be</sub> values and represent the means \u00b1SEM of at least three independent replications. ^Literature values (Varadi et al, 2015) \n\n Table 2 [<sup>35</sup>S]GTPYS Functional assays<sup>3</sup> in transfected cell lines </p> mIVSOR mKOR mDOR </p> Compd, . </p> _ EC<sub>S0</sub> (nM ) E<sub>max</sub> (%) EC<sub>S0</sub> (n ) E<sub>max</sub> (%) EC<sub>5Q</sub> (nM ) E<sub>max</sub> (%) IC<sub>50</sub> (nM)</p>IBNtxA 0.49 \u00b1 0.12 101 \u00b1 3 0.22 \u00b1 0.02 102 \u00b1 4 4.08 \u00b1 0.67 95 \u00b1 2 </p> MP1104 0.21 \u00b1 0.03 103 \u00b1 2 0.027 \u00b1 0.002 104 \u00b1 2 0.41 \u00b1 0.11 88 \u00b1 0</p> P1202 0.32 \u00b1 0.03 68 \u00b1 1 0.13 \u00b1 0.02 94 \u00b1 5 4 \u00b1 1.6 71 \u00b1 2</p> P1207 1.29 \u00b10.65 41 \u00b1 1 1.52 \u00b1 0.07 39.3 \u00b1 1.3 nd 10-15% 27.34\u00b11.95</p>IVIP1208 1.13 \u00b1 0.05 54 \u00b1 0.7 1.36 \u00b1 0.23 43 \u00b1 0.8 nd 10-15% 11.39\u00b1Q.3</p>IVI P1305 0.7 \u00b1 0.1 81.2 \u00b1 16 7.4 \u00b1 1.8 42.2 \u00b1 5.3 31.7 \u00b1 3.6 22\u00b1 0.9 </p> MP1601 0.5 \u00b1 0.2 45 \u00b1 4.6 3 \u00b1 0.7 72 \u00b1 4.5 10 \u00b1 1.6 67 \u00b1 3.9 </p> DAIV!GO 3.4 \u00b1 0.2 </p> U5Q,488h - - 9.5 \u00b1 1.8 </p> DPDPE - - 16.2 \u00b1 5.1 </p>aEfficacy data were determined using an agonist induced stimulation of [<sup>35</sup>SJGTPyS binding assay. Efficacy is represented as ECso (nM) and percent maximal stimulation (E<sub>arn</sub>) relative to standard agonist DAMGO (mMOR), DPDPE (mDOR), or U50,488H (mKOR) at 1 mM. To determine the antagonistic properties of a compound, membranes were incubated with 100 nM of the appropriate agonist by varying its concentrations. Results are presented as nM \u00b1 SEM from three independent experiments performed as triplicate. </p> At rodent receptors in BRET assays, M PI 202 retained balanced agonism at rKOR (bias factor=(3.39, FIG. 3C), although showing a diminished potency on ?-arrestin2 recruitment at mMOR relative to DAMGO, resulting in a G-protein bias factor at MOR of 58 in BRET assays (FIG. 2C). </p>C. Predicted engagement of the TM5-ECL2 region promotes G-protein bias </p>Differences in the bias profiles of MP1104, IBNtxA, and MP1202 suggested distinct interaction modes of these ligands at MOR and KOR. Both the ligand-based and the receptor- based structure design approaches were relied upon to understand the observed pharmacology.</p>In terms of ligand structure, the three ligands have two structural variations among them: the presence/absence of C14-OH and the saturation/unsaturation of the ring C (FIG. 4B). The similarity of the bias profiles for IBNtxA and MPl 202 suggested that C 14-OH is not important for bias. However, the contrast between the strong bias of IBNtxA and MP1202 and balanced agonism of MP1104 at MOR suggested a useful SAR between the conformatio",
    "st preference for the ring C chair form and interactions with the TM5-ECL2 region at both MOR and KOR MR12Q7 and MP1208 (FIGS. 4B, 7C-D and 7G-H) were selected and synthesized (Example 1). </p> Table 5: Docking scores for proposed analogs of MR12Q2, where m-iodo group is substituted with a polar moiety (R). </p> Scores for chair</p>Serial R Chair score Boat score </p> preference</p>1 -mX! 1<sub>2</sub> -55.35 -58.47 +3.12 </p> 2 -m\\(( 1 1 :) \u00b7 -51.81 -48 34 -3.47 </p> 3 -mOH -54.81 -57.34 +2.53 </p> 4 (MP1207) -mCH<sub>2</sub>NH<sub>2</sub> -55.99 -45.9 -10.09 </p> 5 -m CH2CH2NH2 -59.42 -51 79 -7.63 </p>6 -mCH2CH2.CH2.NH2 -64.07 -49.91 -14.16 </p> 7 -mCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> -52.42 -49.67 -2.75 </p> 8 -mgaunidine -76.29 -66.34 -9.95 </p> 9 (MP1208) -mCH2guanidine -86.24 -65.88 -20.36 </p> 10 -mCOguanidine -82.09 -77.53 -4.56 </p> 1 1 -PCH2NH2 -57.63 -60.77 +3.14 </p> 12 -mCHzOH -53.91 -55.43 + 1.5 </p>Functional studies using cAMP inhibition and Tango assays at human opioid receptors showed that both MP1207 and MP1208 are G-protein biased agonists at hKOR with bias factors of 8 and 23 (FIGS. 7A &amp; 7B) respectively. At hMOR, no recruitment of arrestin was seen for either ligand at all, consistent with a strongly biased G-protein partial agonism at MOR as well (FIGS. 7E &amp; 7F). In binding assays, both MP1207 ( -amine group) and MP1208 (rn~ guanidine group) showed similar affinities at mMOR ( K; 0.23 nM and 0.34 nM) and mKOR (Ki-0.39 and 0.28 nM) with substantial selectivity over mDQR (Kr=T5.62 and 19 28 nM) (Table 2). In [<sup>3,</sup>S]GTPyS binding assays both MP1207 and 1208 were partial agonists at both mKOR and mMOR, still maintaining very high potency at mKOR (ECso-l .S and 1 4nM) and at mMOR (ECscfH .3 and 1. InM). At mDOR both MP1207 and 1208 show only weak efficacy. (Table 2 &amp; 6). Similar results of partial agonism at mMOR (FIG. 2D) and rKQR (FIG. 3D) with no recruitment of |3arrestin-2 were seen when rodent opioid receptors were used in BRET \n\n assays. The arrestin recruitment signal for both MR12Q7 and MP1208 at hMOR, mMOR and rKQR were too low for the bias factors at these receptors to be calculated. </p>Table 6, Functional studies at DOR using sAJVlP inhibition &amp; Tango-arrestin and BRET assays A Functional data at hDGR using cAMP inhibition and Tango-arrestin assays </p> eAMP inhibition Arrestin recruitment </p> Compd.</p><img id=\"imgf000078_0001\" path=\"imgf000078_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/802032585/WO/20210114/A1/002021/00/73/66/imgf000078_0001.tif\"/></p> IBNtxA 0.43 (9.3 \u00b1 0.03) 106 \u00b11 14.1(7.8 \u00b10.06) 224+5 </p> DPDPE (CTRL.) 0.69 (9.1 \u00b10.07) 100+2 2.99(8.5 \u00b1 0.04) 100\u00b11.5 </p> MP1104 0.40 (9.4 \u00b1 0.04) 99 \u00b11.1 3.73 (8.4 \u00b1 0.06) 189 \u00b15.5 </p> DADLE (CTRL,) 0.66(9.2 \u00b1 0.05) 100 + 1.3 0.349 (9.45 \u00b10.10) 100 \u00b13.2 </p> MP12Q2 8.18(81 \u00b10.06) 99 \u00b12.2 18.14(7.7 \u00b10.25) 26 \u00b13.1 </p> DADLE (CTRL.) I.45(8.8 \u00b10.06) 100+2 8.41(8.1 \u00b10.08) 100 \u00b12.7 </p> M"
]